tbuckley/cabot-search huggingface dataset:
Plasma EBV DNA Concentration Correlates with FDG Pet in Nasopharyngeal Carcinoma Treated with Induction Chemotherapy
Authors: M. Rahal, H. Abdullah, H. Halawani, H. Zagloul, A. Al Buali, A.A. Alfaraj, H. Abdulkhalek, E.A. Hassan, A. Ahluwalia, F. Medhat
Journal: Annals of Oncology (2012)
Interstitial Pulmonary Disorder in Patients with Esophageal Squamous Cell Carcinoma Treated with Docetaxel after Chemoradiotherapy
Authors: Y. Ezoe, M. Muto, K. Ueda, Y. Ozaki, I. Aoyama, T. Horimatsu, S. Morita, S. Miyamoto, T. Chiba
Journal: Annals of Oncology (2012)
Recruit-Tandab AFM13 - Overcoming Limitations of Monoclonal Antibodies in Hodgkin Lymphoma
Authors: E. Zhukovsky, M. Ravic, A. Rothe, M. Topp, A. Younes, S. Knackmuss, U. Reusch, E. Rajkovic, C. Hucke, M. Little
Journal: Annals of Oncology (2012)
Importance of HPV Involvement and FOXP3+ T-Cell Status as Prognostic Factors in Tonsilar Squamous Cell Carcinoma
Authors: K. Park, K.J. Cho, M. Lee, D.H. Yoon, J. Kim, S.Y. Kim, M.W. Han, S.Y. Nam, S.-H. Choi, J.-L. Roh, S.-W. Lee, S.Y. Song, S.-B. Kim
Journal: Annals of Oncology (2012)
Molecular therapies for HCC: Looking outside the box
Authors: Sandrine Faivre, Lorenza Rimassa, Richard S. Finn
Journal: Journal of Hepatology (2020)

Over the past decade, sorafenib has been the only systemic agent with proven clinical efficacy for patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvatinib was shown to be non-inferior to sorafenib, while regorafenib, cabozantinib, and ramucirumab were shown to be superior to placebo in patients failing sorafenib. In addition, trials of immune checkpoint inhibitors reported encouraging efficacy signals. However, apart from alpha-fetoprotein, which is used to select patients for ramucirumab, no biomarkers are available to identify patients that may respond to a specific treatment. Different synergisms have been postulated based on the potential interplay between antiangiogenic drugs and immunotherapy, with several clinical trials currently testing this hypothesis. Indeed, encouraging preliminary results of phase I studies of bevacizumab plus atezolizumab and lenvatinib plus pembrolizumab have led to the design of ongoing phase III trials, including both antiangiogenics and immune checkpoint inhibitors in the front-line setting. Other important phase II studies have tested molecular therapies directed against different novel targets, such as transforming growth factor-beta, MET (hepatocyte growth factor receptor), and fibroblast growth factor receptor 4. These studies integrated translational research with the aim of better defining the biological tumour profile and identifying tumour and blood biomarkers that select patients who may really benefit from a specific molecular therapy. Importantly, good safety profiles make these drugs suitable for future combinations. In this review, we discuss the most recent data on novel combination strategies and targets, as well as looking ahead to the future role of molecular therapies in the treatment of patients with advanced HCC.
Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma
Authors: J. Lukovic, F.A. Alfaraj, M.L. Mierzwa, G.N. Marta, W. Xu, J. Su, F.Y. Moraes, S.H. Huang, S.V. Bratman, B. O’Sullivan, J.J. Kim, J.G. Ringash, J. Waldron, J.R. de Almeida, D.P. Goldstein, K.A. Casper, A.J. Rosko, M.E. Spector, L.P. Kowalski, A. Hope, A. Hosni
Journal: Annals of Oncology (2020)
ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma
Authors: Richard Beasley, Irene Braithwaite, Alex Semprini, Ciléin Kearns, Mark Weatherall, Tim W. Harrison, Alberto Papi, Ian D. Pavord
Journal: European Respiratory Journal (2020)

<b>A practical "anti-inflammatory reliever therapy"-based algorithm based on the GINA 2019 update is presented, together with a prototype action plan to facilitate its implementation.</b>http://bit.ly/33C2s5u
Efficacy of the Irreversible EGFR-HER2 Dual Inhibitor Afatinib in Pretreated Lung Adenocarcinoma
Authors: L. Landi, D. Galetta, C. Bennati, F. Currà, R. Chiari, G. Metro, M. D'Arcangelo, A. Marchetti, F. Cappuzzo, L. Crinò
Journal: Annals of Oncology (2012)
Does Paclitaxel Plus Carboplatin (TC) Substitute for Paclitaxel Plus Cisplatin (TP) in Cervical Cancer Without Prior Platinum Treatment? (SUBSET ANALYSIS OF JAPAN CLINICAL ONCOLOGY GROUP TRIAL (JCOG 0505))
Authors: H. Tanabe, R. Kitagawa, T. Shibata, M. Saito, S. Takakura, A. Okamoto, H. Sasaki, K. Ochiai, H. Yoshikawa, T. Kamura
Journal: Annals of Oncology (2012)
Addition of Darbepoetin Alfa to Sequential High Dose Vip Chemotherapy for Patients with Advanced Metastatic Germ Cell Cancer
Authors: J.T. Hartmann, B. Metzner, C. Binder, H. Mergenthaler, O. Rick, H.G. Sayer, A. Lorch, W.E. Berdel, C. Bokemeyer, T.C. Gauler
Journal: Annals of Oncology (2012)
Endometrial Effects of Tamoxifen and Exemestane in Early Breast Cancer: Final Results of a Randomized Phase III Trial
Authors: O. Garrone, E. Principe, M. Monteverde, M. Occelli, G. Bertelli, B. Favilla, T. Catzeddu, P. Vanella, E. Miraglio, M. Merlano
Journal: Annals of Oncology (2012)
Crazy Paving in Pulmonary Alveolar Proteinosis
Authors: Brian W Allwood, Sami Bennji
Journal: New England Journal of Medicine (2020)

A 34-year-old man presented with dyspnea and a nonproductive cough. A chest CT showed a crazy-paving pattern. Bronchoalveolar lavage was performed, and a diagnosis of pulmonary alveolar proteinosis was made.
Expression of Hypoxia-Induced Factor 1α and Glucose Transporter 1 Correlates with [18F]-Fluoro-2-Deoxy-Glucose Uptake on Positron Emission Tomography and Tumor Aggressiveness in Different Histologic Subtypes of Lung Adenocarcinomas
Authors: Y. Miyata, T. Furukawa, Y. Tsutani, T. Mimae, K. Misumi, T. Yoshiya, Y. Ibuki, M. Okada
Journal: Annals of Oncology (2012)
Dietary prophage inducers and antimicrobials: toward landscaping the human gut microbiome
Authors: Lance Boling, Daniel A. Cuevas, Juris A. Grasis, Han Suh Kang, Ben Knowles, Kyle Levi, Heather Maughan, Katelyn McNair, Maria Isabel Rojas, Savannah E. Sanchez, Cameron Smurthwaite, Forest Rohwer
Journal: Gut Microbes (2020)

The approximately 1011 viruses and microbial cells per gram of fecal matter (dry weight) in the large intestine are important to human health. The responses of three common gut bacteria species, and one opportunistic pathogen, to 117 commonly consumed foods, chemical additives, and plant extracts were tested. Many compounds, including Stevia rebaudiana and bee propolis extracts, exhibited species-specific growth inhibition by prophage induction. Overall, these results show that various foods may change the abundances of gut bacteria by modulating temperate phage and suggests a novel path for landscaping the human gut microbiome.
Using Perivascular Fat Attenuation Index to Monitor Coronary Inflammation in Patients With Psoriasis
Authors: Sharon A. Sutanto, Nicole E. James, Rachel H. Y. Loy
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A Phase I Dose Escalation and Expansion Trial of BKM120, An Oral Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors: Analysis of Pharmacodynamic Biomarker Data
Authors: J. Rodon, J. Bendell, A.R.A. Razak, M.J.A. De Jonge, F. Eskens, E. Di Tomaso, D.W. Sternberg, L. Wang, C. Sarr, J. Baselga
Journal: Annals of Oncology (2012)
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
Authors: Michael R Migden, Nikhil I Khushalani, Anne Lynn S Chang, Karl D Lewis, Chrysalyne D Schmults, Leonel Hernandez-Aya, Friedegund Meier, Dirk Schadendorf, Alexander Guminski, Axel Hauschild, Deborah J Wong, Gregory A Daniels, Carola Berking, Vladimir Jankovic, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, David M Weinreich, George D Yancopoulos, Israel Lowy, Matthew G Fury, Danny Rischin
Journal: The Lancet Oncology (2020)
A Dual bioluminescent reporter transgenic mouse strain for noninvasive bioluminescent imaging of cells that have undergone cre-mediated recombination–a useful model for development research
Authors: Qian Wang, Timothy Dolyle, Yuan Cao, Christopher H. Contag
Journal: Cancer Research (2006)

979  The molecular pathways control normal embryonic development. In different development stage, different genes are activated or silenced. Mouse strains expressing the site-specific recombinase Cre facilitate conditional ablation of gene function when one or several exons of the gene of interest are flanked by loxP sites. Cre expression achieved by classic transgenesis or targeting to an appropriate locus might be tissue specific, temporally restricted or inducible. In such experimental outlines, it is necessary to monitor Cre activity at desired time points as well as to verify that Cre was not active previously during development. Here we describe a transgenic mouse model which has GFP fluorescent gene and two bioluminescent reporter genes Renilla luciferase and Click Beetle Luciferase, preceded by a LoxP-stop-LoxP (L-S-L) cassette–LoxP-Renilla Luciferase-stop-LoxP-Click Beetle Luciferase-eGFP, driven by modified chicken β-actin promoter, which may be useful for identifying the gene expression pattern in different development stage. The β-actin promoter-LoxP-Renilla Luciferase-stop-LoxP-Click beetle Luciferase-eGFP transgenic mice in conjunction with Cre recombinase delivered by a variety of means, allows for spatial and temporal control of gene expression in mouse models. Different tissue cells derived from this strain which expressed Renilla Luciferse would express Click Beetle luciferase and eGFP after Cre-mediated recombination in vitro driven by different promoter. The β-actin promoter-LoxP-Renilla Luciferase-stop-LoxP-Click beetle Luciferase-eGFP mice expressed luciferase and eGFP in a diffuse pattern, as determined by non-invasive, bioluminescent and fluorescent imaging (Xenogen IVIS system) and immunohistology, when crossed to a transgenic mice in which Cre was driven by β-actin promoter (β-actin-Cre). The β-actin promoter-LoxP-Renilla Luciferase-stop-LoxP-Click beetle Luciferase-eGFP transgenic mice should be useful for characterizing Cre mouse strains and for following the fate of cells that have undergone Cre-mediated recombination in vivo.
Disrupt: A Randomized Phase 2 Trial of Ombrabulin (AVE8062) Combined with a Taxane-Platinum Regimen in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
Authors: J. von Pawel, V. Gorbounova, M. Reck, D. Kowalski, A. Allard, M. Chadjaa, A. Rey, J. Bennouna, F. Grossi
Journal: Annals of Oncology (2012)
Prognostic Impact of Phospho-Er-Alpha (PER-α) in Surgically Resected Colon Cancer
Authors: I. López Calderero, A.C. Moya, A.A. Gonzalez, A.C. Carranza, M.C. Conde, S. Molina-Pinelo, M.D.P. Herrera, M.L.L. Miron, P.E. Garcia, R. Garcia-Carbonero
Journal: Annals of Oncology (2012)
多リガンド受容体であるメガリンをコードするLRP2の突然変異はDonnai-Barrow症候群およびfacio-oculo-acoustico-renal症候群を引き起こす
Authors: Kantarci Sibel, Al-Gazali Lihadh, Hill R Sean, Donnai Dian, Black Graeme C M, Bieth Eric, Chassaing Nicolas, Lacombe Didier, Devriendt Koen, Teebi Ahmad, Loscertales Maria, Robson Caroline, Liu Tianming, Maclaughlin David T, Noonan Kristin M, Russell Meaghan K, Walsh Christopher A, Donahoe Patricia K, Pober Barbara R
Journal: Nature Genetics (2007)
Understanding the Value of Response and Early Tumour Shrinkage (ETS) in Pts with Wt kras MCRC Treated with Panitumumab (P) Plus Folfox (F)
Authors: J. Douillard, S. Siena, J. Tabernero, M. Peeters, C. Davison, S. Braun, R. Sidhu
Journal: Annals of Oncology (2012)
Required Capabilities and Infrastructure for Japanese Phase I Institutes: From the Experience of Early Phase Drug Development Operation at Phase I Centers in United States
Authors: T. Shimizu, I. Okamoto, T. Kurata, Y. Fujisaka, J. Tsurutani, M. Nomura, T. Minami, K. Sakaguchi, R. Ohnishi, J. Chang, Y. Hase, K. Nakagawa
Journal: Annals of Oncology (2012)
Targeting cell-extracellular matrix (ECM) interactions to enhance radiation efficacy for breast cancer treatment
Authors: Catherine C. Park, Hui J. Zhang, Evelyn Yao, Mary Helen Barcellos-Hoff, Mina J. Bissell
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

1659 

Background: Cell interactions with the extracellular matrix (ECM) have been shown to affect radiation response in several malignant cell lines, including breast cancer. β1 integrin is a critical mediator of cell-ECM interactions and has been implicated in multiple stages of cancer progression. β1 integrin mediated signaling has been shown to enhance cancer cell survival following radiation (Cordes, 2002). We have previously shown that ionizing radiation (IR) induces persistent and heritable changes in β1 integrin expression and distribution in human mammary epithelial cells cultured in a 3-dimensional laminin-rich culture (3D-rBM). To investigate how β1 integrin signaling modifies radiation response in the context of normal mammary epithelial cells and malignant cells, we tested the ability of β1 integrin inhibitory monoclonal antibody, AIIB2, to modify radiation effects in culture and in vivo. Methods: To model normal and malignant breast cells in their physiologic microenvironment, we propagated both non-malignant and tumorigenic breast cells in 3D-rBM. Non-malignant S1 cells form organized acinar structures while tumorigenic cell lines, T4-2, MDA-MB-231 and MCF-7 form disorganized, invasive colonies. To disrupt cell-ECM signaling via β1 integrin, β1 integrin inhibitory antibody, AIIB2 was added to cultures alone or 24 hours prior to a single administration of ionizing radiation at doses from 0-8 Gy. Cultures were assayed 48-72 hours after treatment for proliferation (by presence of Ki-67 nuclear antigen) and apoptosis (by TUNEL). To test the effects of these treatments in vivo, T4-2 xenografts were established in adult female nu -/- mice and given AIIB2 alone or in combination with single fractions of ionizing radiation (0-8 Gy). Tumors were evaluated for growth and for proliferation and apoptosis ex-vivo. Results: Inhibition of β1 integrin with monoclonal AIIB2 in combination with ionizing radiation increased the cytostatic effect in malignant tumors in 3D-rBM compared to antibody alone. In contrast, there was little effect on non-malignant cell line, S-1 in culture. In vivo, the combination of AIIB2 and IR had an increased cytostatic effect on T4-2 xenografts compared to AIIB2 alone with minimal toxicity. Conclusions: Malignant breast cell colonies are susceptible to decreased growth and increased apoptosis with β1 integrin inhibitory antibody and IR. In contrast, β1 integrin signaling in the context of normal tissue organization is refractory to β1 integrin inhibition and IR. The combination of β1 integrin inhibition using monoclonal antibody AIIB2 enhances the therapeutic efficacy of IR in malignant breast cancer and has potential for therapeutic clinical applications.
Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy
Authors: Songlei Zhou, Yukun Huang, Yu Chen, Shanshan Liu, Minjun Xu, Tianze Jiang, Qingxiang Song, Gan Jiang, Xiao Gu, Xiaoling Gao, Jun Chen
Journal: Biomaterials (2020)
Efficacy and Patient (PT)-Reported Outcomes (PROS) aith Selumetinib (AZD6244, ARRY-142866; SEL) + Docetaxel (DOC) in Kras-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): A Randomized, Phase II Trial
Authors: P.A. Janne, A.T. Shaw, J.R. Pereira, G. Jeannin, J.F. Vansteenkiste, C. Barrios, F.A. Franke, L. Grinsted, I. Smith, L. Crino
Journal: Annals of Oncology (2012)
Extreme Downregulation of Chromosome Y and Cancer Risk in Men
Authors: Alejandro Cáceres, Aina Jene, Tonu Esko, Luis A Pérez-Jurado, Juan R González
Journal: JNCI Journal of the National Cancer Institute (2019)

Understanding the biological differences between sexes in cancer is essential for personalized treatment and prevention. We hypothesized that the extreme downregulation of chromosome Y gene expression (EDY) is a signature of cancer risk in men and the functional mediator of the reported association between the mosaic loss of chromosome Y (LOY) and cancer.We advanced a method to measure EDY from transcriptomic data. We studied EDY across 47 nondiseased tissues from the Genotype Tissue-Expression Project (n = 371) and its association with cancer status across 12 cancer studies from The Cancer Genome Atlas (n = 1774) and seven other studies (n = 7562). Associations of EDY with cancer status and presence of loss-off function mutations in chromosome X were tested with logistic regression models, and a Fisher's test was used to assess genome-wide association of EDY with the proportion of copy number gains. All statistical tests were two-sided.EDY was likely to occur in multiple nondiseased tissues (P < .001) and was statistically significantly associated with the EGFR tyrosine kinase inhibitor resistance pathway (false discovery rate = 0.028). EDY strongly associated with cancer risk in men (odds ratio [OR] = 3.66, 95% confidence interval [CI] = 1.58 to 8.46, P = .002), adjusted by LOY and age, and its variability was largely explained by several genes of the nonrecombinant region whose chromosome X homologs showed loss-of-function mutations that co-occurred with EDY during cancer (OR = 2.82, 95% CI = 1.32 to 6.01, P = .007). EDY associated with a high proportion of EGFR amplifications (OR = 5.64, 95% CI = 3.70 to 8.59, false discovery rate < 0.001) and EGFR overexpression along with SRY hypomethylation and nonrecombinant region hypermethylation, indicating alternative causes of EDY in cancer other than LOY. EDY associations were independently validated for different cancers and exposure to smoking, and its status was accurately predicted from individual methylation patterns.EDY is a male-specific signature of cancer susceptibility that supports the escape from X-inactivation tumor suppressor hypothesis for genes that protect women compared with men from cancer risk.
Pre-Hospital Administration of Epinephrine in Pediatric Patients With Out-of-Hospital Cardiac Arrest
Authors: Tasuku Matsuyama, Sho Komukai, Junichi Izawa, Koichiro Gibo, Masashi Okubo, Kosuke Kiyohara, Takeyuki Kiguchi, Taku Iwami, Bon Ohta, Tetsuhisa Kitamura
Journal: Journal of the American College of Cardiology (2020)
Docetaxel (D), Gemcitabine (G) and Bevacizumab (BEV) as Salvage Chemotherapy (CT) for HER-2 Negative Metastatic Breast Cancer (MBC)
Authors: E. Kontopodis, C. Christophylakis, N. Kentepozidis, I. Boukovinas, S. Giassas, E. Saloustros, A. Kalykaki, V. Bozionelou, V. Georgoulias, D. Mavroudis
Journal: Annals of Oncology (2012)
Preoperative Chemoradiation with S-1–Oxaliplatin in Patients with Locally Advanced Rectal Cancer: Results of a Phase II Study and the Role of Diffusion Weighted Magnetic Resonance Imaging for Prediction of Pathologic Responses
Authors: T.W. Kim, K.-P. Kim, Y.S. Hong, J.-L. Lee, S.Y. Kim, Y.S. Park
Journal: Annals of Oncology (2012)
Measuring and Improving the Quality of Heart Failure Care Globally
Authors: Sidney C. Smith, Gregg C. Fonarow, Dong Zhao
Journal: JAMA Network Open (2020)

Aakriti Gupta, MD, MS; Yuan Yu, MD, PhD; Qi Tan, MPH; Shuling Liu, PhD; Frederick A. Masoudi, MD, MSPH; Xue Du, MD, PhD; Jian Zhang, MD, PhD; Harlan M. Krumholz, MD, SM; Jing Li, MD, PhD
Randomised Phase II Trial of Oral Vinorelbine (N) and Cisplatin (P) or Pemetrexed and C (PC) in First Line Advanced Non Squamous (NSCC) Non Small Cell Lung Cancer (NSCLC) Patients (PTS). Navotrial01: Final Results
Authors: E.H. Tan, L. Havel, M.J. Krzakowski, J. Kollmeier, R. Gervais, E. Dansin, M. Serke, S. Malassé, F. Biville-Hedouin, J. Bennouna
Journal: Annals of Oncology (2012)
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
Authors: Davide Capodanno, Deepak L. Bhatt, John W. Eikelboom, Keith A. A. Fox, Tobias Geisler, C. Michael Gibson, Jose Ramon Gonzalez-Juanatey, Stefan James, Renato D. Lopes, Roxana Mehran, Gilles Montalescot, Manesh Patel, P. Gabriel Steg, Robert F. Storey, Pascal Vranckx, Jeffrey I. Weitz, Robert Welsh, Uwe Zeymer, Dominick J. Angiolillo
Journal: Nature Reviews Cardiology (2020)
P-0288 Safety and Efficacy of Metronomic Capecitabine in Pre-Operative Chemoradiotherapy for Locally Advanced Rectal Cancer (Larc)
Authors: Francesco Sponziello, Antonella Marino, Margherita Cinefra, Angelo Nacci, Annamaria Quaranta, Pietro Rizzo, Nicola Calvani, Laura Orlando, Paola Schiavone, Palma Fedele, Chiara Caliolo, Maria D'Amico, Francesco Tramacere, Maurizio Portaluri, Saverio Cinieri
Journal: Annals of Oncology (2012)
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial
Authors: Irwin Walker, Tony Panzarella, Stephen Couban, Felix Couture, Gerald Devins, Mohamed Elemary, Geneviève Gallagher, Holly Kerr, John Kuruvilla, Stephanie J Lee, John Moore, Thomas Nevill, Gizelle Popradi, Jean Roy, Kirk R Schultz, David Szwajcer, Cynthia Toze, Ronan Foley
Journal: The Lancet Haematology (2020)
More Evidence of the Association of Diet With Human Testicular Function—Fish Oil Supplements
Authors: Albert Salas-Huetos
Journal: JAMA Network Open (2020)

Tina Kold Jensen, PhD; Lærke Priskorn, PhD; Stine A. Holmboe, PhD; Feiby L. Nassan, ScD, MBBCh; Anna-Maria Andersson, PhD; Christine Dalgård, PhD; Jørgen Holm Petersen, PhD; Jorge E. Chavarro, MD, ScD; Niels Jørgensen, PhD
A Phase II Trial of Definitive Chemoradiotherapy with S-1 and Cisplatin for Locally advanced Oesophageal Cancer
Authors: H. Iwase, M. Shimada, T. Tsuzuki, N. Ryuge, Y. Kida, B. Kato, M. Esaki, Y. Tanaka, N. Urata
Journal: Annals of Oncology (2012)
Colorectal Cancer in Patients with Type 2 Diebetes Mellitus: Retrospective Analysis of 741 Cases
Authors: M. Messina, E. Sinagra, S. Dolcimascolo, C.A. Rizzolo, F. Puccia, F. Mocciaro, S. Marasà, G. Perricone, D. Bedognetti, D. Sinagra
Journal: Annals of Oncology (2012)
P-0260 Impact of Ldh, Cea snd CA 19.9 On Response, Overall and Progression-Free Survival in Metastatic Colorectal Cancer Treated with Bevacizumab
Authors: Cristina Pissarro, Mónica Mariano, Florbela Dias, Isabel Pazos, Nuno Bonito, João Ribeiro, Paula Jacinto, Helena Gervásio
Journal: Annals of Oncology (2012)
Phase 1 Study of Veliparib With Concurrent Whole Brain Radiation Therapy (WBRT) in Patients (PTS) With Brain Metastases (METS)
Authors: M.P. Mehta, W.J. Curran, D. Wang, F. Wang, L. Kleinberg, A. Brade, J. Qian, T. Leahy,, B. Desai, V.L. Giranda
Journal: Annals of Oncology (2012)